Article Text

PDF
New challenges in viral hepatitis
  1. David Thomas1,
  2. Fabien Zoulim2,3
  1. 1Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  2. 2Lyon University, Institut Universitaire de France, France
  3. 3INSERM U1052, Viral Hepatitis Research Team, Lyon, France
  1. Correspondence to David Thomas, Chief of Infectious Diseases, Johns Hopkins School of Medicine, Suite 437, 1830 Monument Street, Baltimore, MD 21205, USA; dthomas{at}jhmi.edu

Abstract

Over the past few decades there has been remarkable progress in viral hepatitis. Beginning with discovery of the viral agents, we now have reliable methods to diagnose and monitor all hepatitis virus infections, as well significant advances in treatment and prevention. Nonetheless, important challenges remain. This supplement to Gut looks forward to the next generation of challenges in the field of viral hepatitis, and this introductory article highlights several key issues.

  • Hepatitis A
  • hepatitis B
  • hepatitis C
  • hepatitis E
  • hepatitis D

Statistics from Altmetric.com

Footnotes

  • Competing interests David Thomas received donations of antiretroviral drugs from Gilead and Merck and served on a scientific advisory board for Merck.

  • We thank Novartis for the financial support that has made this supplement possible. As always, Gut retains sole responsibility for all editorial content.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.